REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

Type de document :
Communication dans un congrès
The 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Mar 2017, Barcelone, Spain. Neuroendocrinology, 105 (Suppl. 1), pp.187 (J8), 2017, 〈https://www.karger.com/Article/Pdf/484263〉
Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01664217
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : jeudi 14 décembre 2017 - 15:52:55
Dernière modification le : vendredi 27 juillet 2018 - 15:04:02

Identifiants

  • HAL Id : hal-01664217, version 1

Collections

Citation

C. Lepage, L. Dahan, J.-L. Legoux, K. Le Malicot, R. Guimbaud, et al.. REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors . The 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Mar 2017, Barcelone, Spain. Neuroendocrinology, 105 (Suppl. 1), pp.187 (J8), 2017, 〈https://www.karger.com/Article/Pdf/484263〉. 〈hal-01664217〉

Partager

Métriques

Consultations de la notice

64